로딩 중…
지수 로딩 중…
Optipharm.CO.,LTD
153710· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,710+0.75%
2026-08-04
Financials
Valuation Metrics
Optipharm.CO.,LTD's Market Cap is ₩691B. At end of 2025 it was ₩748B. Ranked #1481 of 2,436 in KR market (top 61%), #845 of 1,649 on KOSDAQ (top 51%), #163 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.10B KRW | KR#1,481/2,436 Sec#163/234 |
| Revenue | 22.79B KRW | KR#2,108/2,436 Sec#150/234 |
| Net Income | -2.11B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 39.58B KRW | KR#2,272/2,436 Sec#209/234 |
| Net Assets | 24.76B KRW | KR#2,216/2,436 Sec#203/234 |
| Employees | 77 | KR#1,807/2,436 Sec#152/234 |
| Value | ||
| P/B | 2.79x | KR#2,115/2,436 Sec#166/234 |
| P/S | 3.03x | KR#2,025/2,436 Sec#129/234 |
| FCF Yield | -5.88% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -8.54% | KR#1,870/2,436 Sec#144/234 |
| ROA | -5.34% | KR#1,909/2,436 Sec#143/234 |
| Op. Margin | -8.79% | KR#1,955/2,436 Sec#133/234 |
| Revenue Growth | 9.01% | KR#964/2,436 Sec#86/234 |
| Financial Health | ||
| Debt Ratio | 159.82% | KR#1,317/2,436 Sec#150/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -4.06B KRW | KR#1,459/2,436 Sec#114/234 |
| Cash | 2.22B KRW | KR#2,224/2,436 Sec#213/234 |
| Current Ratio | 1.17x | KR#1,612/2,436 Sec#167/234 |
| Performance | ||
| 1Y Return | -5.42% | KR#753/2,436 Sec#54/234 |
| 1M Return | 4.67% | KR#241/2,436 Sec#16/234 |
| From 52W High | -24.64% | KR#277/2,436 Sec#17/234 |
| 1Y MDD | -31.29% | KR#239/2,436 Sec#16/234 |
| Trading | ||
| Volume | 3,601 shares | KR#2,221/2,436 Sec#221/234 |
| Foreign Own. | 1.13% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -144 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,688 KRW | KR#2,114/2,436 Sec#180/234 |
Company Info
OptiPharm, established in 2000 and listed on KOSDAQ in 2018, specializes in animal-related businesses, including disease diagnosis, pharmaceuticals, and bacteriophage. Since 2006, it has developed an independent disease appraisal system and diagnostic products. Leveraging original technologies like transgenic technology and animal-related infrastructure, the company is expanding into human-related ventures such as bacteriophage-based disease treatments and xenotransplantation development.